Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients With Essential Hypertension and Primary Hypercholesterolemia
- 1 December 1999
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 34 (6), 1281-1286
- https://doi.org/10.1161/01.hyp.34.6.1281
Abstract
Abstract —Certain hydroxymethylglutaryl coenzyme A reductase inhibitors, ie, statins, may cause vasodilation by restoring the endothelial dysfunction that frequently accompanies hypertension and hypercholesterolemia. Several studies have found that a blood pressure reduction is associated with the use of statins, but conclusive evidence from controlled trials is lacking. After an 8-week placebo and diet run-in period, 30 persons with moderate hypercholesterolemia and untreated hypertension (total cholesterol 6.29±0.52 mmol/L, systolic and diastolic blood pressure 149±6 and 97±2 mm Hg) were randomized in a double-blind manner to placebo or pravastatin (20 to 40 mg/d) in a crossover design. In 25 participants who completed the 32-week trial, pravastatin decreased total and LDL cholesterol (both −1.09 mmol/L, P =0.001), systolic and diastolic blood pressure (−8 and −5 mm Hg, both P =0.001), and pulse pressure (−3 mm Hg, P =0.011) and blunted the blood pressure increase caused by the cold pressor test (−4 mm Hg, P =0.005) compared with placebo. It also reduced the level of circulating endothelin-1 ( P =0.001). The blood pressure results were virtually unchanged in stratified analyses according to gender and age and in intention-to-treat analyses that included the 5 patients who dropped out of the study. When the participants were taking either placebo or pravastatin, blood pressure was not significantly correlated with total or LDL cholesterol or with circulating endothelin-1. Pravastatin decreases systolic, diastolic, and pulse pressures in persons with moderate hypercholesterolemia and hypertension. This antihypertensive effect may contribute to the documented health benefits of certain statins.Keywords
This publication has 18 references indexed in Scilit:
- Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatinAtherosclerosis, 1997
- The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human ??-thrombinBlood Coagulation & Fibrinolysis, 1996
- Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged menThe American Journal of Cardiology, 1996
- Impaired Endothelium-Dependent Vasodilation of Coronary Resistance Vessels in Hypercholesterolemic Patients.Internal Medicine, 1996
- Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)The American Journal of Cardiology, 1995
- Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertensionThe American Journal of Cardiology, 1995
- Short Term Effects of Pravastatin on Blood Pressure in Hypercholesterolaemic Hypertensive PatientsBlood Pressure, 1994
- Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension.JCI Insight, 1993
- Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertensionThe American Journal of Cardiology, 1993
- Raised plasma endothelin-I concentration following cold pressor testBiochemical and Biophysical Research Communications, 1990